ID   M92-001
AC   CVCL_1G27
SY   M92 001
DR   Cosmic; 1211152
DR   Wikidata; Q54903653
RX   PubMed=10952317;
RX   PubMed=23039341;
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_LM77 ! M93-007
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 08-07-15; Last updated: 21-03-23; Version: 6
//
RX   PubMed=10952317; DOI=10.1038/35020115;
RA   Bittner M., Meltzer P.S., Chen Y.-D., Jiang Y., Seftor E.A.,
RA   Hendrix M.J.C., Radmacher M.D., Simon R.M., Yakhini Z., Ben-Dor A.,
RA   Sampas N., Dougherty E., Wang E., Marincola F.M., Gooden G.C., Lueders J.,
RA   Glatfelter A., Pollock P.M., Carpten J.D., Gillanders E.M., Leja D.,
RA   Dietrich K., Beaudry C., Berens M.E., Alberts D.S., Sondak V.K.,
RA   Hayward N.K., Trent J.M.;
RT   "Molecular classification of cutaneous malignant melanoma by gene
RT   expression profiling.";
RL   Nature 406:536-540(2000).
//
RX   PubMed=23039341; DOI=10.1186/1476-4598-11-75; PMCID=PMC3554420;
RA   Byron S.A., Loch D.C., Wellens C.L., Wortmann A., Wu J.-Y., Wang J.,
RA   Nomoto K., Pollock P.M.;
RT   "Sensitivity to the MEK inhibitor E6201 in melanoma cells is
RT   associated with mutant BRAF and wildtype PTEN status.";
RL   Mol. Cancer 11:75.1-75.15(2012).
//